시장보고서

상품코드

1761149

아프리카의 항암제 시장 규모 및 예측(2021-2031년), 지역 점유율, 동향, 성장 기회 분석 보고서 : 약물 종류별, 적응증별, 제형별, 치료법별, 부문별, 국가별

Africa Anticancer Drugs Market Size and Forecast 2021 - 2031, Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class, Indication, Dosage Form, Therapy, Sector, and Country

발행일: 2025년 06월 | 리서치사:

The Insight Partners | 페이지 정보: 영문 315 Pages | 배송안내 : 즉시배송

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

아프리카의 항암제 시장 규모는 2024년 18억 1,000만 달러에서 2031년 32억 3,000만 달러에 달할 것으로 예상됩니다. 이 시장은 2025-2031년 CAGR 8.8%로 성장할 것으로 추정됩니다.

본 보고서의 아프리카 항암제 시장 예측은 해당 시장 공간의 이해관계자들이 성장 전략을 수립하는 데 도움이 될 것입니다. 암 발병률의 증가와 암에 대한 인식을 개선하기 위한 이니셔티브의 급증은 아프리카 항암제 시장의 성장을 촉진하는 주요 요인으로 작용하고 있습니다.

암 치료를 가속화하는 인공지능

인공지능(AI)은 항암제 시장에서 유전자 다양성, 임상 데이터 부족, 개인화된 치료 접근성 제한과 관련된 심각한 문제를 해결하기 위한 혁신의 힘으로 부상하고 있습니다. 전 세계적으로 암 환자가 크게 증가함에 따라 AI는 신약 개발을 가속화하고, 치료를 최적화하며, 지역 혁신을 촉진하고 있습니다. 암 검진, 진단 및 치료에 AI를 적용하면 암을 조기에 발견할 수 있는 길이 열리고, 환자 개개인에 맞는 새로운 치료 계획의 개발이 가속화될 수 있습니다.

케이프타운 대학교, 글락소 스미스클라인, 노바티스, 남아프리카공화국 의학연구위원회가 협력하는 프로젝트 아프리카 GRADIENT는 아프리카의 유전자 프로파일에 맞게 약물을 조정하는 데 있어 AI의 역할을 예시하고 있습니다. 이 이니셔티브는 약물 반응에 영향을 미치는 유전적 돌연변이를 고려함으로써 아프리카 사람들을 위해 설계된 치료법의 효능을 향상시키는 것을 목표로 합니다. 이러한 접근 방식은 치료가 더 효과적이고 부작용이 적으며 환자의 결과를 크게 개선할 수 있도록 보장합니다. 또한 AI는 방대한 양의 생물학적 데이터를 분석하여 잠재적인 약물 후보를 식별함으로써 신약 개발 과정을 가속화할 수 있습니다. 인실리코 메디신(Insilico Medicine)과 같은 개발업체들은 저분자 치료법을 설계하고 신약 타겟을 발견하기 위해 AI 기반 플랫폼을 채택하여 의약품 개발 기간을 수년에서 수개월로 단축하고 있습니다. 2023년 4월, 세계 제약사 아스트라제네카(AstraZeneca)는 남아프리카공화국의 의료 기술 기업 MedSol AI Solutions와 손잡고 유방암 발견에 AI를 활용하기 위해 협력하기로 했습니다. 양사의 협력의 핵심은 몇 초 안에 유방암을 식별할 수 있는 최첨단 Wi-Fi 지원 초음파 탐침입니다. 특히 소외된 지역의 조기 진단을 돕기 위해 지방 진료소에 Melusi Breast AI Rapid Detection 앱이 배포될 예정입니다. 전용 의뢰 시스템이 이 이니셔티브를 뒷받침하여 양성 판정을 받은 여성들이 적시에 치료를 받을 수 있도록 돕습니다. 이처럼 아프리카의 암 치료에 AI를 통합하면 치료 결과를 개선하고 의학 연구 및 개발의 자립을 촉진할 수 있으며, AI를 활용하면 아프리카 국가들은 유전적 다양성과 개별화된 치료에 대한 제한된 접근으로 인한 고유한 문제를 해결하고 보다 공평한 의료 솔루션으로 가는 길을 열 수 있습니다. 따라서 AI는 맞춤형 치료를 가능하게 하고, 의약품 개발을 가속화하며, 종합적인 연구를 촉진함으로써 아프리카의 항암제 시장에 새로운 트렌드를 가져오고 있습니다.

약제 종류별로 아프리카 항암제 시장은 세포독성 약물, 표적 치료제, 호르몬제, 면역치료제, 유전자 치료제, 방사성의약품, 기타로 분류됩니다. 세포독성 의약품 부문은 2024년 가장 큰 점유율을 차지했습니다. 표적 치료제 부문은 2025-2031년 가장 높은 CAGR을 기록할 것으로 예상됩니다.

적응증별로 아프리카 항암제 시장은 폐암, 위암, 대장암, 유방암, 전립선암, 기타로 분류됩니다. 폐암 부문은 2024년에 가장 큰 시장 점유율을 차지했으며, 유방암 부문은 2025-2031년 동안 시장에서 가장 높은 CAGR을 기록할 것으로 추정됩니다.

치료법별로 아프리카 항암제 시장은 화학요법, 표적 치료제, 면역치료제, 유전자 치료제, 방사성의약품치료제, 기타로 분류됩니다. 화학요법 부문은 2024년 가장 큰 시장 점유율을 차지했으며, 2025-2031년 동안 가장 높은 CAGR을 기록할 것으로 추정됩니다.

제형별로 아프리카 항암제 시장은 정제 및 캡슐, 주사제, 액제로 분류됩니다. 정제 및 캡슐제는 2024년 가장 큰 시장 점유율을 차지했으며, 2025-2031년 시장 CAGR이 가장 높을 것으로 추정됩니다.

부문별로는 공공과 민간 부문으로 나뉘며, 2024년 시장 규모에서 공공 부문이 큰 비중을 차지했고, 2025-2031년 CAGR은 민간 부문이 더 높을 것으로 추정됩니다.

본 보고서 작성에 참고한 주요 1차 및 2차 정보는 GLOBOCAN-IARC, WHO Cancer Country Profiles, WHO Global Health Observatory, UN Comtrade Database, IAEA DIRAC, World Bank, WHO Global Health Expenditure Database, Ministries of Health (e.g., Egypt CAPA, Nigeria NHIS), African Medicines Agency (AMA), BMI Fitch)입니다.

아프리카의 항암제 시장 : 주요 시장 역학
시장 성장 촉진요인
- 암 이환율 상승
- 암에 대한 인식 개선 활동 증가
시장 성장 억제요인
- 저렴한 가격의 항암제를 구할 수 없음
시장 기회
- 임상시험 수 급증
향후 동향
- 암 치료를 가속하는 인공지능
성장 촉진요인과 억제요인의 영향

제6장 아프리카의 항암제 시장 : 시장 분석

아프리카의 항암제 시장 매출, 2021-2031년
아프리카의 항암제 시장 예측 분석

제7장 아프리카의 항암제 시장 분석 : 약물 종류별

표적치료제
호르몬제
면역치료제
유전자치료제
방사성의약품
기타

제8장 아프리카의 항암제 시장 분석 : 적응증별

폐암
위암
대장암
유방암
전립선암
기타

제9장 아프리카의 항암제 시장 분석 : 제형별

정제·캡슐제
주사제
액제

제10장 아프리카의 항암제 시장 분석 : 치료법별

화학요법
표적요법
면역요법
유전자 치료
방사성의약품 요법
기타

제11장 아프리카의 항암제 시장 분석 : 부문별

민간
공공

제12장 아프리카의 항암제 시장 : 지역별 분석

아프리카
- 남아프리카공화국
- 이집트
- 알제리
- 모로코
- 튀니지
- 나이지리아
- 케냐
- 에티오피아
- 가나
- 코트디부아르
- 세네갈
- 리비아
- 기타 아프리카

제13장 경쟁 구도

히트맵 분석 : 주요 기업별
기업 포지셔닝과 집중도

제14장 업계 상황

시장 이니셔티브
파트너십과 제휴
기타 개발

제15장 기업 개요

Amgen Inc
Gilead Sciences Inc
Novartis AG
F. Hoffmann-La Roche Ltd
BeiGene Ltd
Takeda Pharmaceutical Co Ltd
GSK Plc
Sanofi SA
Cipla Ltd
Johnson & Johnson
Aspen Holdings
Pfizer Inc
AstraZeneca Plc
Merck & Co Inc
Daiichi Sankyo Co Ltd

제16장 부록

ksm 25.07.07

The Africa anticancer drugs market is expected to reach US$ 3.23 billion by 2031 from US$ 1.81 billion in 2024. The market is estimated to grow with a CAGR of 8.8% from 2025 to 2031.

The Africa anticancer drugs market forecast presented in this report can help stakeholders in this marketplace plan their growth strategies. The increasing incidence of cancer and surging initiatives to improve cancer awareness are the key factors propelling the Africa anticancer drugs market growth.

Artificial Intelligence Accelerating Cancer Care

Artificial Intelligence (AI) is emerging as a transformative force in the anticancer drugs market, addressing critical challenges associated with genetic diversity, scarce clinical data, and limited access to personalized treatments. Amid the vast increase in cancer cases across the continent, AI is accelerating drug discovery, optimizing treatments, and fostering local innovation. The practical application of AI in cancer screening, diagnosis, and care opens the door for early cancer identification and accelerates the development of new treatment plans tailored to each patient.

Project Africa GRADIENT, a collaboration between the University of Cape Town, GlaxoSmithKline, Novartis, and the South African Medical Research Council, exemplifies AI's role in tailoring drugs to African genetic profiles. This initiative aims to enhance the efficacy of treatments designed for African populations by considering genetic variations that influence drug responses. This approach ensures that therapies are more effective and have fewer side effects, significantly improving patient outcomes. Additionally, AI accelerates the drug discovery process by analyzing vast amounts of biological data to identify potential drug candidates. Companies such as Insilico Medicine employ AI-driven platforms to design small-molecule treatments and discover drug targets, reducing drug development timelines from years to months. This rapid development is crucial for addressing the increasing cancer burden in Africa, where early detection and treatment options are often limited. In April 2023, AstraZeneca (a global pharmaceutical company) joined forces with South African health-tech firm MedSol AI Solutions to advance the use of AI in breast cancer detection. Their collaboration centers around a cutting-edge Wi-Fi-enabled ultrasound probe capable of identifying breast cancer within seconds. Their Melusi Breast AI rapid detection app will be deployed in rural clinics to support early diagnosis, particularly in underserved areas. A dedicated referral system backs the initiative to ensure that women with positive results can access timely therapeutic interventions. Thus, AI integration into the cancer care landscape in Africa would enhance treatment outcomes and promote self-reliance in medical research and development. By harnessing AI, African nations can address the unique challenges posed by genetic diversity and limited access to personalized care, paving the way for more equitable healthcare solutions. Hence, by enabling personalized treatments, accelerating drug development, and fostering inclusive research, AI is setting new trends in the Africa anticancer drugs market.

Based on drug class, the Africa anticancer drugs market is segmented into cytotoxic drugs, targeted drugs, hormonal drugs, immunotherapy drugs, gene therapy drugs, radiopharmaceuticals, and others. The cytotoxic drugs segment held the largest share in 2024. The targeted drugs segment is expected to register the highest CAGR during 2025-2031.

Based on indication, the Africa anticancer drugs market is segmented into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, and others. The lung cancer segment held the largest market share in 2024, and the breast cancer segment is estimated to register the highest CAGR in the market during 2025-2031.

In terms of therapy type, the Africa anticancer drugs market is categorized into chemotherapy, targeted therapy, immunotherapy, gene therapy, radiopharmaceutical therapy, and others. The chemotherapy segment held the largest market share in 2024, and the same segment is estimated to register the highest CAGR in the market during 2025-2031.

Based on dosage form, the Africa anticancer drugs market is categorized into tablet and capsule, injectable, and liquid. The tablet and capsule segment held the largest market share in 2024, and the same segment is estimated to register the highest CAGR in the market during 2025-2031.

By sector, the market is bifurcated into public and private. The public segment held a larger share of the market in 2024. The private segment is estimated to register a higher CAGR during 2025-2031.

A few of the major primary and secondary sources referred to while preparing the report on the Africa anticancer drugs market are the GLOBOCAN - IARC, WHO Cancer Country Profiles, WHO Global Health Observatory, UN Comtrade Database, IAEA DIRAC, World Bank, WHO Global Health Expenditure Database, Ministries of Health (e.g., Egypt CAPA, Nigeria NHIS), African Medicines Agency (AMA), BMI Fitch).

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Analyst Market Outlook

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:

4. African Anticancer Drugs Market Landscape

4.1 Overview
4.2 PEST Analysis
4.3 Cancer Prevalence, By Country
4.4 Cancer Therapeutics: Pricing Analysis, 2024
4.5 Import-export Scenario in Africa
4.6 Ecosystem Analysis
- 4.6.1 List of Vendors in the Value Chain

5. African Anticancer Drugs Market - Key Market Dynamics

5.1 African Anticancer Drugs Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Rising Cancer Incidence
- 5.2.2 Increasing Initiatives to Improve Cancer Awareness
5.3 Market Restraints
- 5.3.1 Unaffordability and Limited Availability of Cancer Drugs
5.4 Market Opportunities
- 5.4.1 Surging Number of Clinical Trials
5.5 Future Trends
- 5.5.1 Artificial Intelligence Accelerating Cancer Care
5.6 Impact of Drivers and Restraints:

6. African Anticancer Drugs Market - Global Market Analysis

6.1 African Anticancer Drugs Market Revenue (US$ Million), 2021-2031
6.2 African Anticancer Drugs Market Forecast Analysis

7. African Anticancer Drugs Market Analysis - by Drug Class Type

7.1 Cytotoxic Drugs
- 7.1.1 Overview
- 7.1.2 Cytotoxic Drugs: African Anticancer Drugs Market - Revenue and Forecast to 2031 (US$ Million)
7.2 Targeted Drugs
- 7.2.1 Overview
- 7.2.2 Targeted Drugs: African Anticancer Drugs Market - Revenue and Forecast to 2031 (US$ Million)
7.3 Hormonal Drugs
- 7.3.1 Overview
- 7.3.2 Hormonal Drugs: African Anticancer Drugs Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Immunotherapy Drugs
- 7.4.1 Overview
- 7.4.2 Immunotherapy Drugs: African Anticancer Drugs Market - Revenue and Forecast to 2031 (US$ Million)
7.5 Gene Therapy Drugs
- 7.5.1 Overview
- 7.5.2 Gene Therapy Drugs: African Anticancer Drugs Market - Revenue and Forecast to 2031 (US$ Million)
7.6 Radiopharmaceuticals
- 7.6.1 Overview
- 7.6.2 Radiopharmaceuticals: African Anticancer Drugs Market - Revenue and Forecast to 2031 (US$ Million)
7.7 Others
- 7.7.1 Overview
- 7.7.2 Others: African Anticancer Drugs Market - Revenue and Forecast to 2031 (US$ Million)

8. African Anticancer Drugs Market Analysis - by Indication

8.1 Lung Cancer
- 8.1.1 Overview
- 8.1.2 Lung Cancer: African Anticancer Drugs Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Stomach Cancer
- 8.2.1 Overview
- 8.2.2 Stomach Cancer: African Anticancer Drugs Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Colorectal Cancer
- 8.3.1 Overview
- 8.3.2 Colorectal Cancer: African Anticancer Drugs Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Breast Cancer
- 8.4.1 Overview
- 8.4.2 Breast Cancer: African Anticancer Drugs Market - Revenue and Forecast to 2031 (US$ Million)
8.5 Prostrate Cancer
- 8.5.1 Overview
- 8.5.2 Prostrate Cancer: African Anticancer Drugs Market - Revenue and Forecast to 2031 (US$ Million)
8.6 Others
- 8.6.1 Overview
- 8.6.2 Others: African Anticancer Drugs Market - Revenue and Forecast to 2031 (US$ Million)

9. African Anticancer Drugs Market Analysis - by Dosage Form

9.1 Tablet and Capsule
- 9.1.1 Overview
- 9.1.2 Tablet and Capsule: African Anticancer Drugs Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Injectable
- 9.2.1 Overview
- 9.2.2 Injectable: African Anticancer Drugs Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Liquid
- 9.3.1 Overview
- 9.3.2 Liquid: African Anticancer Drugs Market - Revenue and Forecast to 2031 (US$ Million)

10. African Anticancer Drugs Market Analysis - by Therapy

10.1 Chemotherapy
- 10.1.1 Overview
- 10.1.2 Chemotherapy: African Anticancer Drugs Market - Revenue and Forecast to 2031 (US$ Million)
10.2 Targeted Therapy
- 10.2.1 Overview
- 10.2.2 Targeted Therapy: African Anticancer Drugs Market - Revenue and Forecast to 2031 (US$ Million)
10.3 Immunotherapy
- 10.3.1 Overview
- 10.3.2 Immunotherapy: African Anticancer Drugs Market - Revenue and Forecast to 2031 (US$ Million)
10.4 Gene Therapy
- 10.4.1 Overview
- 10.4.2 Gene Therapy: African Anticancer Drugs Market - Revenue and Forecast to 2031 (US$ Million)
10.5 Radiopharmaceutical Therapy
- 10.5.1 Overview
- 10.5.2 Radiopharmaceutical Therapy: African Anticancer Drugs Market - Revenue and Forecast to 2031 (US$ Million)
10.6 Others
- 10.6.1 Overview
- 10.6.2 Others: African Anticancer Drugs Market - Revenue and Forecast to 2031 (US$ Million)

11. African Anticancer Drugs Market Analysis - by Sector

11.1 Private
- 11.1.1 Overview
- 11.1.2 Private: African Anticancer Drugs Market - Revenue and Forecast to 2031 (US$ Million)
11.2 Public
- 11.2.1 Overview
- 11.2.2 Public: African Anticancer Drugs Market - Revenue and Forecast to 2031 (US$ Million)

12. African Anticancer Drugs Market - Geographical Analysis

12.1 Africa
- 12.1.1 African Anticancer Drugs Market Overview
- 12.1.2 African Anticancer Drugs Market - Revenue, 2021 - 2031 (US$ Million)
  - 12.1.2.1 African Anticancer Drugs Market - Revenue and Forecast Analysis - by Drug Class Type
  - 12.1.2.2 African Anticancer Drugs Market - Revenue and Forecast Analysis - by Cytotoxic Drugs
  - 12.1.2.3 African Anticancer Drugs Market - Revenue and Forecast Analysis - by Targeted Drugs
  - 12.1.2.4 African Anticancer Drugs Market - Revenue and Forecast Analysis - by Hormonal Drugs
  - 12.1.2.5 African Anticancer Drugs Market - Revenue and Forecast Analysis - by Indication
  - 12.1.2.6 African Anticancer Drugs Market - Revenue and Forecast Analysis - by Dosage Form
  - 12.1.2.7 African Anticancer Drugs Market - Revenue and Forecast Analysis - by Therapy
  - 12.1.2.8 African Anticancer Drugs Market - Revenue and Forecast Analysis - by Sector
- 12.1.3 African Anticancer Drugs Market - Revenue and Forecast Analysis - by Country
  - 12.1.3.1 South Africa: African Anticancer Drugs Market - Revenue, 2021 - 2031 (US$ Million)
    - 12.1.3.1.1 South Africa: African Anticancer Drugs Market Breakdown, by Drug Class Type
    - 12.1.3.1.2 South Africa: African Anticancer Drugs Market Breakdown, by Cytotoxic Drugs
    - 12.1.3.1.3 South Africa: African Anticancer Drugs Market Breakdown, by Targeted Drugs
    - 12.1.3.1.4 South Africa: African Anticancer Drugs Market Breakdown, by Hormonal Drugs
    - 12.1.3.1.5 South Africa: African Anticancer Drugs Market Breakdown, by Indication
    - 12.1.3.1.6 South Africa: African Anticancer Drugs Market Breakdown, by Dosage Form
    - 12.1.3.1.7 South Africa: African Anticancer Drugs Market Breakdown, by Therapy
    - 12.1.3.1.8 South Africa: African Anticancer Drugs Market Breakdown, by Sector
  - 12.1.3.2 Egypt: African Anticancer Drugs Market - Revenue, 2021 - 2031 (US$ Million)
    - 12.1.3.2.1 Egypt: African Anticancer Drugs Market Breakdown, by Drug Class Type
    - 12.1.3.2.2 Egypt: African Anticancer Drugs Market Breakdown, by Cytotoxic Drugs
    - 12.1.3.2.3 Egypt: African Anticancer Drugs Market Breakdown, by Targeted Drugs
    - 12.1.3.2.4 Egypt: African Anticancer Drugs Market Breakdown, by Hormonal Drugs
    - 12.1.3.2.5 Egypt: African Anticancer Drugs Market Breakdown, by Indication
    - 12.1.3.2.6 Egypt: African Anticancer Drugs Market Breakdown, by Dosage Form
    - 12.1.3.2.7 Egypt: African Anticancer Drugs Market Breakdown, by Therapy
    - 12.1.3.2.8 Egypt: African Anticancer Drugs Market Breakdown, by Sector
  - 12.1.3.3 Algeria: African Anticancer Drugs Market - Revenue, 2021 - 2031 (US$ Million)
    - 12.1.3.3.1 Algeria: African Anticancer Drugs Market Breakdown, by Drug Class Type
    - 12.1.3.3.2 Algeria: African Anticancer Drugs Market Breakdown, by Cytotoxic Drugs
    - 12.1.3.3.3 Algeria: African Anticancer Drugs Market Breakdown, by Targeted Drugs
    - 12.1.3.3.4 Algeria: African Anticancer Drugs Market Breakdown, by Hormonal Drugs
    - 12.1.3.3.5 Algeria: African Anticancer Drugs Market Breakdown, by Indication
    - 12.1.3.3.6 Algeria: African Anticancer Drugs Market Breakdown, by Dosage Form
    - 12.1.3.3.7 Algeria: African Anticancer Drugs Market Breakdown, by Therapy
    - 12.1.3.3.8 Algeria: African Anticancer Drugs Market Breakdown, by Sector
  - 12.1.3.4 Morocco: African Anticancer Drugs Market - Revenue, 2021 - 2031 (US$ Million)
    - 12.1.3.4.1 Morocco: African Anticancer Drugs Market Breakdown, by Drug Class Type
    - 12.1.3.4.2 Morocco: African Anticancer Drugs Market Breakdown, by Cytotoxic Drugs
    - 12.1.3.4.3 Morocco: African Anticancer Drugs Market Breakdown, by Targeted Drugs
    - 12.1.3.4.4 Morocco: African Anticancer Drugs Market Breakdown, by Hormonal Drugs
    - 12.1.3.4.5 Morocco: African Anticancer Drugs Market Breakdown, by Indication
    - 12.1.3.4.6 Morocco: African Anticancer Drugs Market Breakdown, by Dosage Form
    - 12.1.3.4.7 Morocco: African Anticancer Drugs Market Breakdown, by Therapy
    - 12.1.3.4.8 Morocco: African Anticancer Drugs Market Breakdown, by Sector
  - 12.1.3.5 Tunisia: African Anticancer Drugs Market - Revenue, 2021 - 2031 (US$ Million)
    - 12.1.3.5.1 Tunisia: African Anticancer Drugs Market Breakdown, by Drug Class Type
    - 12.1.3.5.2 Tunisia: African Anticancer Drugs Market Breakdown, by Cytotoxic Drugs
    - 12.1.3.5.3 Tunisia: African Anticancer Drugs Market Breakdown, by Targeted Drugs
    - 12.1.3.5.4 Tunisia: African Anticancer Drugs Market Breakdown, by Hormonal Drugs
    - 12.1.3.5.5 Tunisia: African Anticancer Drugs Market Breakdown, by Indication
    - 12.1.3.5.6 Tunisia: African Anticancer Drugs Market Breakdown, by Dosage Form
    - 12.1.3.5.7 Tunisia: African Anticancer Drugs Market Breakdown, by Therapy
    - 12.1.3.5.8 Tunisia: African Anticancer Drugs Market Breakdown, by Sector
  - 12.1.3.6 Nigeria: African Anticancer Drugs Market - Revenue, 2021 - 2031 (US$ Million)
    - 12.1.3.6.1 Nigeria: African Anticancer Drugs Market Breakdown, by Drug Class Type
    - 12.1.3.6.2 Nigeria: African Anticancer Drugs Market Breakdown, by Cytotoxic Drugs
    - 12.1.3.6.3 Nigeria: African Anticancer Drugs Market Breakdown, by Targeted Drugs
    - 12.1.3.6.4 Nigeria: African Anticancer Drugs Market Breakdown, by Hormonal Drugs
    - 12.1.3.6.5 Nigeria: African Anticancer Drugs Market Breakdown, by Indication
    - 12.1.3.6.6 Nigeria: African Anticancer Drugs Market Breakdown, by Dosage Form
    - 12.1.3.6.7 Nigeria: African Anticancer Drugs Market Breakdown, by Therapy
    - 12.1.3.6.8 Nigeria: African Anticancer Drugs Market Breakdown, by Sector
  - 12.1.3.7 Kenya: African Anticancer Drugs Market - Revenue, 2021 - 2031 (US$ Million)
    - 12.1.3.7.1 Kenya: African Anticancer Drugs Market Breakdown, by Drug Class Type
    - 12.1.3.7.2 Kenya: African Anticancer Drugs Market Breakdown, by Cytotoxic Drugs
    - 12.1.3.7.3 Kenya: African Anticancer Drugs Market Breakdown, by Targeted Drugs
    - 12.1.3.7.4 Kenya: African Anticancer Drugs Market Breakdown, by Hormonal Drugs
    - 12.1.3.7.5 Kenya: African Anticancer Drugs Market Breakdown, by Indication
    - 12.1.3.7.6 Kenya: African Anticancer Drugs Market Breakdown, by Dosage Form
    - 12.1.3.7.7 Kenya: African Anticancer Drugs Market Breakdown, by Therapy
    - 12.1.3.7.8 Kenya: African Anticancer Drugs Market Breakdown, by Sector
  - 12.1.3.8 Ethiopia: African Anticancer Drugs Market - Revenue, 2021 - 2031 (US$ Million)
    - 12.1.3.8.1 Ethiopia: African Anticancer Drugs Market Breakdown, by Drug Class Type
    - 12.1.3.8.2 Ethiopia: African Anticancer Drugs Market Breakdown, by Cytotoxic Drugs
    - 12.1.3.8.3 Ethiopia: African Anticancer Drugs Market Breakdown, by Targeted Drugs
    - 12.1.3.8.4 Ethiopia: African Anticancer Drugs Market Breakdown, by Hormonal Drugs
    - 12.1.3.8.5 Ethiopia: African Anticancer Drugs Market Breakdown, by Indication
    - 12.1.3.8.6 Ethiopia: African Anticancer Drugs Market Breakdown, by Dosage Form
    - 12.1.3.8.7 Ethiopia: African Anticancer Drugs Market Breakdown, by Therapy
    - 12.1.3.8.8 Ethiopia: African Anticancer Drugs Market Breakdown, by Sector
  - 12.1.3.9 Ghana: African Anticancer Drugs Market - Revenue, 2021 - 2031 (US$ Million)
    - 12.1.3.9.1 Ghana: African Anticancer Drugs Market Breakdown, by Drug Class Type
    - 12.1.3.9.2 Ghana: African Anticancer Drugs Market Breakdown, by Cytotoxic Drugs
    - 12.1.3.9.3 Ghana: African Anticancer Drugs Market Breakdown, by Targeted Drugs
    - 12.1.3.9.4 Ghana: African Anticancer Drugs Market Breakdown, by Hormonal Drugs
    - 12.1.3.9.5 Ghana: African Anticancer Drugs Market Breakdown, by Indication
    - 12.1.3.9.6 Ghana: African Anticancer Drugs Market Breakdown, by Dosage Form
    - 12.1.3.9.7 Ghana: African Anticancer Drugs Market Breakdown, by Therapy
    - 12.1.3.9.8 Ghana: African Anticancer Drugs Market Breakdown, by Sector
  - 12.1.3.10 Cote d Ivoire (Ivory Coast): African Anticancer Drugs Market - Revenue, 2021 - 2031 (US$ Million)
    - 12.1.3.10.1 Cote d Ivoire (Ivory Coast): African Anticancer Drugs Market Breakdown, by Drug Class Type
    - 12.1.3.10.2 Cote d Ivoire (Ivory Coast): African Anticancer Drugs Market Breakdown, by Cytotoxic Drugs
    - 12.1.3.10.3 Cote d Ivoire (Ivory Coast): African Anticancer Drugs Market Breakdown, by Targeted Drugs
    - 12.1.3.10.4 Cote d Ivoire (Ivory Coast): African Anticancer Drugs Market Breakdown, by Hormonal Drugs
    - 12.1.3.10.5 Cote d Ivoire (Ivory Coast): African Anticancer Drugs Market Breakdown, by Indication
    - 12.1.3.10.6 Cote d Ivoire (Ivory Coast): African Anticancer Drugs Market Breakdown, by Dosage Form
    - 12.1.3.10.7 Cote d Ivoire (Ivory Coast): African Anticancer Drugs Market Breakdown, by Therapy
    - 12.1.3.10.8 Cote d Ivoire (Ivory Coast): African Anticancer Drugs Market Breakdown, by Sector
  - 12.1.3.11 Senegal: African Anticancer Drugs Market - Revenue, 2021 - 2031 (US$ Million)
    - 12.1.3.11.1 Senegal: African Anticancer Drugs Market Breakdown, by Drug Class Type
    - 12.1.3.11.2 Senegal: African Anticancer Drugs Market Breakdown, by Cytotoxic Drugs
    - 12.1.3.11.3 Senegal: African Anticancer Drugs Market Breakdown, by Targeted Drugs
    - 12.1.3.11.4 Senegal: African Anticancer Drugs Market Breakdown, by Hormonal Drugs
    - 12.1.3.11.5 Senegal: African Anticancer Drugs Market Breakdown, by Indication
    - 12.1.3.11.6 Senegal: African Anticancer Drugs Market Breakdown, by Dosage Form
    - 12.1.3.11.7 Senegal: African Anticancer Drugs Market Breakdown, by Therapy
    - 12.1.3.11.8 Senegal: African Anticancer Drugs Market Breakdown, by Sector
  - 12.1.3.12 Libya: African Anticancer Drugs Market - Revenue, 2021 - 2031 (US$ Million)
    - 12.1.3.12.1 Libya: African Anticancer Drugs Market Breakdown, by Drug Class Type
    - 12.1.3.12.2 Libya: African Anticancer Drugs Market Breakdown, by Cytotoxic Drugs
    - 12.1.3.12.3 Libya: African Anticancer Drugs Market Breakdown, by Targeted Drugs
    - 12.1.3.12.4 Libya: African Anticancer Drugs Market Breakdown, by Hormonal Drugs
    - 12.1.3.12.5 Libya: African Anticancer Drugs Market Breakdown, by Indication
    - 12.1.3.12.6 Libya: African Anticancer Drugs Market Breakdown, by Dosage Form
    - 12.1.3.12.7 Libya: African Anticancer Drugs Market Breakdown, by Therapy
    - 12.1.3.12.8 Libya: African Anticancer Drugs Market Breakdown, by Sector
  - 12.1.3.13 Rest of Africa: African Anticancer Drugs Market - Revenue, 2021 - 2031 (US$ Million)
    - 12.1.3.13.1 Rest of Africa: African Anticancer Drugs Market Breakdown, by Drug Class Type
    - 12.1.3.13.2 Rest of Africa: African Anticancer Drugs Market Breakdown, by Cytotoxic Drugs
    - 12.1.3.13.3 Rest of Africa: African Anticancer Drugs Market Breakdown, by Targeted Drugs
    - 12.1.3.13.4 Rest of Africa: African Anticancer Drugs Market Breakdown, by Hormonal Drugs
    - 12.1.3.13.5 Rest of Africa: African Anticancer Drugs Market Breakdown, by Indication
    - 12.1.3.13.6 Rest of Africa: African Anticancer Drugs Market Breakdown, by Dosage Form
    - 12.1.3.13.7 Rest of Africa: African Anticancer Drugs Market Breakdown, by Therapy
    - 12.1.3.13.8 Rest of Africa: African Anticancer Drugs Market Breakdown, by Sector

13. Competitive Landscape

13.1 Heat Map Analysis by Key Players
13.2 Company Positioning and Concentration

14. Industry Landscape

14.1 Overview
14.2 Market Initiative
14.3 Partnerships and Collaborations
14.4 Other Developments

15. Company Profiles

15.1 Amgen Inc
- 15.1.1 Key Facts
- 15.1.2 Business Description
- 15.1.3 Products and Services
- 15.1.4 Financial Overview
- 15.1.5 SWOT Analysis
- 15.1.6 Key Developments
15.2 Gilead Sciences Inc
- 15.2.1 Key Facts
- 15.2.2 Business Description
- 15.2.3 Products and Services
- 15.2.4 Financial Overview
- 15.2.5 SWOT Analysis
- 15.2.6 Key Developments
15.3 Novartis AG
- 15.3.1 Key Facts
- 15.3.2 Business Description
- 15.3.3 Products and Services
- 15.3.4 Financial Overview
- 15.3.5 SWOT Analysis
- 15.3.6 Key Developments
15.4 F. Hoffmann-La Roche Ltd
- 15.4.1 Key Facts
- 15.4.2 Business Description
- 15.4.3 Products and Services
- 15.4.4 Financial Overview
- 15.4.5 SWOT Analysis
- 15.4.6 Key Developments
15.5 BeiGene Ltd
- 15.5.1 Key Facts
- 15.5.2 Business Description
- 15.5.3 Products and Services
- 15.5.4 Financial Overview
- 15.5.5 SWOT Analysis
- 15.5.6 Key Developments
15.6 Takeda Pharmaceutical Co Ltd
- 15.6.1 Key Facts
- 15.6.2 Business Description
- 15.6.3 Products and Services
- 15.6.4 Financial Overview
- 15.6.5 SWOT Analysis
- 15.6.6 Key Developments
15.7 GSK Plc
- 15.7.1 Key Facts
- 15.7.2 Business Description
- 15.7.3 Products and Services
- 15.7.4 Financial Overview
- 15.7.5 SWOT Analysis
- 15.7.6 Key Developments
15.8 Sanofi SA
- 15.8.1 Key Facts
- 15.8.2 Business Description
- 15.8.3 Products and Services
- 15.8.4 Financial Overview
- 15.8.5 SWOT Analysis
- 15.8.6 Key Developments
15.9 Cipla Ltd
- 15.9.1 Key Facts
- 15.9.2 Business Description
- 15.9.3 Products and Services
- 15.9.4 Financial Overview
- 15.9.5 SWOT Analysis
- 15.9.6 Key Developments
15.10 Johnson & Johnson
- 15.10.1 Key Facts
- 15.10.2 Business Description
- 15.10.3 Products and Services
- 15.10.4 Financial Overview
- 15.10.5 SWOT Analysis
- 15.10.6 Key Developments
15.11 Aspen Holdings
- 15.11.1 Key Facts
- 15.11.2 Business Description
- 15.11.3 Products and Services
- 15.11.4 Financial Overview
- 15.11.5 SWOT Analysis
- 15.11.6 Key Developments
15.12 Pfizer Inc
- 15.12.1 Key Facts
- 15.12.2 Business Description
- 15.12.3 Products and Services
- 15.12.4 Financial Overview
- 15.12.5 SWOT Analysis
- 15.12.6 Key Developments
15.13 AstraZeneca Plc
- 15.13.1 Key Facts
- 15.13.2 Business Description
- 15.13.3 Products and Services
- 15.13.4 Financial Overview
- 15.13.5 SWOT Analysis
- 15.13.6 Key Developments
15.14 Merck & Co Inc
- 15.14.1 Key Facts
- 15.14.2 Business Description
- 15.14.3 Products and Services
- 15.14.4 Financial Overview
- 15.14.5 SWOT Analysis
- 15.14.6 Key Developments
15.15 Daiichi Sankyo Co Ltd
- 15.15.1 Key Facts
- 15.15.2 Business Description
- 15.15.3 Products and Services
- 15.15.4 Financial Overview
- 15.15.5 SWOT Analysis

16. Appendix

16.1 About The Insight Partners
16.2 Glossary of Terms